These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 20348843

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. SBE13 joins the family of Polo-like kinase 1 (Plk1) inhibitors.
    Liu X.
    Cell Cycle; 2010 Feb 01; 9(3):445-6. PubMed ID: 20130451
    [No Abstract] [Full Text] [Related]

  • 5. Should I stall or should I cycle? An inhibitor for Polo-like Kinase 1 with distinct roles in primary cells.
    Posern G.
    Cell Cycle; 2011 Apr 01; 10(7):1029-30. PubMed ID: 21412046
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Developing polo-like kinase 1 inhibitors.
    Huang X, Xie Z, Liao C.
    Future Med Chem; 2020 May 01; 12(10):869-871. PubMed ID: 32233804
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition.
    Lange L, Hemmerich P, Spänkuch B.
    Oncotarget; 2015 Sep 22; 6(28):25801-14. PubMed ID: 26317649
    [Abstract] [Full Text] [Related]

  • 10. Polo-like kinase 1 inhibitors SBE13 and BI 2536 induce different responses in primary cells.
    Eckerdt F.
    Cell Cycle; 2011 Apr 01; 10(7):1027-8. PubMed ID: 21415595
    [No Abstract] [Full Text] [Related]

  • 11. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM, Shi Y, Quan J.
    ChemMedChem; 2015 Jan 01; 10(1):158-63. PubMed ID: 25196850
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Small-molecule inhibitors for targeting polo-like kinase 1.
    Kolosenko I, Palm-Apergi C.
    Future Med Chem; 2020 Aug 01; 12(16):1457-1460. PubMed ID: 32638616
    [No Abstract] [Full Text] [Related]

  • 14. Drugs by numbers: reaction-driven de novo design of potent and selective anticancer leads.
    Spänkuch B, Keppner S, Lange L, Rodrigues T, Zettl H, Koch CP, Reutlinger M, Hartenfeller M, Schneider P, Schneider G.
    Angew Chem Int Ed Engl; 2013 Apr 22; 52(17):4676-81. PubMed ID: 23166089
    [Abstract] [Full Text] [Related]

  • 15. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN, Louwen F, Zimmer B, Yuan J.
    Oncotarget; 2015 Mar 30; 6(9):6611-26. PubMed ID: 25483104
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB, Woo SU, Yim H.
    J Cell Physiol; 2015 Dec 30; 230(12):3057-67. PubMed ID: 25975351
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Targeting polo-like kinase: learning too little too late?
    Olmos D, Swanton C, de Bono J.
    J Clin Oncol; 2008 Dec 01; 26(34):5497-9. PubMed ID: 18955441
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.
    Chem Biol; 2008 May 01; 15(5):459-66. PubMed ID: 18482698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.